Immunotherapy trial helps cancer patients with tumours live 40% longer
by Andrew Gregory Health editor in Chicago from Science | The Guardian on (#6XNSV)
Experts praise groundbreaking results from therapy using genetically modified Car T-cells
Cancer patients treated with a pioneering immunotherapy that genetically modifies their own cells to wipe out tumours live 40% longer, according to exciting" and groundbreaking" results from a world-first clinical trial.
Car T-cell therapy is a new form of immunotherapy where a patient's own T-cells - a type of white blood cell - are tweaked in a lab to target and kill cancer cells. The designer cells are then infused back into their bloodstream to fight the disease.
Continue reading...